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Abstract
While true antimicrobial resistance to Chlamydia trachomatis is a rare occurrence, repeat chlamydia infections
continue to be reported following treatment with a single 1 g dose of azithromycin or week long doxycycline – with
considerable more concern about azithromycin treatment failure. While most repeat positive cases are likely to be
reinfections, emerging evidence indicates treatment failure may play a role. Current data suggests that there may
are differences in the efficacy of the drugs between rectal and non-rectal sites of infection and factors such as
immune response, drug pharmacokinetics, organism load, auto-inoculation from rectum to cervix in women and the
genital microbiome may play a role in treatment failure. Other possible reasons for repeat infection include the low
discriminatory power of NAAT tests to differentiate between viable and nonviable organisms and failure to detect
LGV infection. This review will present the current evidence regarding the management challenges for urogenital
and anorectal chlamydia infections and provide some suggestions for where future research efforts are needed to
address important knowledge gaps in this area and provide stronger evidence for the development of robust
treatment guidelines.
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Introduction
In an era of increasing antimicrobial resistance, it is for-
tunate that Chlamydia trachomatis (CT) resistance re-
mains rare [1]. However, there has been considerable
recent concern about the efficacy of treatment for uro-
genital [2] and anorectal CT infections, [3] with particu-
lar worry about the efficacy of single dose azithromycin.
Given that treatment failure could lead to ongoing CT
transmission and an increased risk of complications as-
sociated with chlamydia, including HIV transmission,
[4–6] it is vital that we understand the mechanisms of
treatment failure and have access to highly efficacious
treatments.
Concern about treatment failure has arisen because of
high repeat CT infection rates observed in community
cohorts of women in the UK (25.5 %) [7] and among
women attending general practice clinics in Australia
(22.3 %) [8] and the UK (29.9 %) [9]. Among men, repeat
infection rates of up to 18.3 % have been reported for
urethral infection [10] and up to 21.7 % for repeat rectal
infections [11]. However, repeat infection does not ne-
cessarily mean treatment failure; repeat infection follow-
ing treatment can also occur as a result of re-infection
or it could be a false positive diagnosis due to the detec-
tion of non-viable (dead) chlamydia nucleic acid that is
still clearing after treatment. Non-viable chlamydia nu-
cleic acid can take about three weeks to clear after treat-
ment [12].
The treatment guidelines for uncomplicated urogenital
CT infections in the United States (US), [13] Europe
[14] and Australia [15] all consistently recommend a sin-
gle 1 g dose of azithromycin as the first line treatment.
However the recommendations for the treatment of
anorectal infections are less uniform with the US recom-
mending single dose azithromycin while Europe and
Australia recommending one week of doxycycline
(100 mg twice daily) as first line therapy.
In this review, we will discuss the latest treatment effi-
cacy data for anogenital chlamydia infection, examine
the evidence about why treatment efficacy may vary be-
tween azithromycin and doxycycline and identify areas
where further research is needed. We will refer to 1
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gram single dose of azithromycin as “azithromycin” and
7 days doxycycline (100 mg twice per day) as “doxycycline”
from hereon.
Azithromycin and doxycycline efficacy for the treatment
of anogenital chlamydia infection
A 2002 meta-analysis of randomised controlled trials
(RCTs) examining the treatment of urogenital (cervical
or urethral) chlamydia found no difference in efficacy
between azithromycin (97 % efficacy) and doxycycline
(98 %) (efficacy difference of 1.0 %; 95 % CI: -1.0 %,
2.0 %) [16]. However 11 of the 12 included studies used
culture or immunoassays rather than sensitive Nucleic
Acid Amplification Tests (NAAT) to assess microbial
cure so it is possible that the efficacy estimates may have
been overestimated [17]. Given such concerns and grow-
ing literature citing increasing reports of repeat positive
infections, this meta-analysis was updated in 2014 [18].
The results of this analysis reported an overall efficacy of
97.4 % for doxycycline and 94.3 % for azithromycin
(efficacy difference of 2.6 %; 95 % CI: 0.5 %, 4.7 %), sug-
gesting a small, but statistically significant difference in
favour of doxycycline. When this analysis was restricted
to studies of symptomatic men only, there was a greater
difference in efficacy in favour of doxycycline (efficacy
difference of 5.5 %; 95 % CI: −1.4 %, 12.4 %). A recent
meta-analysis of treatment efficacy for anorectal chlamydia
infection found a much greater difference in efficacy:
99.6 % for doxycycline and 82.9 % for azithromycin
(efficacy difference of 19.9 %; 95 % CI: 11.4 %, 28.3 %) [19].
Should we be alarmed at these results? For urogenital
chlamydia treatment, no, we shouldn’t be alarmed.
There was considerable variability in the quality of the
studies included in the meta-analysis reducing the va-
lidity of their results. Firstly, only 17 % (4/23) of the tri-
als included were double-blinded RCTs. Double blinding
is necessary to ensure the risk of re-infection is similar
between treatment arms because it is possible that tak-
ing a week long course of daily doxycycline may deter
people from resuming sexual activity while taking treat-
ment, making them less susceptible to re-infection. Sec-
ondly, most trials were based in high risk populations
attending sexual health clinics. These populations are
not representative of the majority of those who get chla-
mydia which is a largely asymptomatic infection.
However, for anorectal chlamydia infection we still
don’t know which drug is the most efficacious. No RCTs
comparing doxycycline and azithromycin were identi-
fied; the meta-analysis was based entirely on obser-
vational studies with 75 % (6/8) of the studies being
retrospective case note reviews. Observational studies
are at considerable risk of confounding and other biases
that threaten the validity of their results. However, if azi-
thromycin efficacy is indeed 83 %, then this is much
lower than the 95 % threshold recommended by the
World Health Organisation (WHO) for STI treatments
and it shouldn’t be used for rectal chlamydia [20]. A
treatment trial comparing azithromycin with doxycycline
for the treatment of anorectal chlamydia infection is
urgently needed to provide quality evidence to inform
treatment guidelines.
Antimicrobial resistance is unlikely to play a significant
role in anogenital chlamydia treatment efficacy
To date, no prospective clinical studies have focused on
the potential role of antibiotic resistance as a cause for
chlamydia treatment failure. However, clinical treatment
failures have been reported and the chlamydia isolates
from these failures have been found to demonstrate
multi-drug resistance in vitro, including resistance to
tetracyclines (including doxycycline) and macrolides
(including azithromycin) [21–26] - with mutations in a
23S rRNA gene been associated with in vitro resistance
to macrolides [27, 28]. This resistance usually exhibits a
heterotypic pattern where an infection has a small pro-
portion of resistant organisms among a mostly suscep-
tible population [1]. The phenomenon of heterotypic
resistance has also been described in Staphylococcus
spp. [29] and may evolve because of selective pressure
from frequent exposure to antimicrobials [24, 30, 31].
This is further supported by in vitro demonstrations that
chlamydia easily and rapidly develops resistance after
serial passage in sub-inhibitory concentrations of macro-
lides [31]. To date, chlamydia strains exhibiting homo-
typic resistance in humans, a pattern where the whole
population of organisms survive post treatment, have
not been identified [1].
Chlamydia antimicrobial sensitivity testing is challen-
ging, with few laboratories conducting it today. Mini-
mum inhibitory concentrations (MICs) for chlamydia
can vary depending on the cell line utilized and when
the antimicrobial is added post infection [31]. There are
few recent MIC data for chlamydia and as a result, it is
not known whether there has been any “MIC creep”
(decreased antimicrobial sensitivity) over time. However,
given increasing concern about antimicrobial resistance
for other STIs, it is imperative that we play closer atten-
tion to potential chlamydia resistance and collect chla-
mydia isolates from people who appear to have failed
treatment for susceptibility testing.
Organism load may be important for treatment efficacy
Heterotypic resistance is demonstrated in vitro at high
levels of chlamydial organism load, but is not evident at
lower levels of organism load leading to the hypothesis
that treatment efficacy may reduce as organism load in-
creases. A recent systematic review found that organism
load is higher at the anorectal site than at cervical or
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urethral sites raising the possibility that anorectal infec-
tions may be more susceptible to treatment failure be-
cause of heterotypic resistance [32]. A recent Australian
study investigating the association of organism load with
repeat anorectal chlamydia infection among men, found
that for every log10 increase in organism load, the odds of
a repeat anorectal infection within 3 months of treatment
with azithromycin increased by 70 % (OR 1.7; 95 % CI:
1.2–2.5) providing support for the hypothesis that high
loads contribute to treatment failure [33].
The systematic review also found that those with symp-
tomatic anogenital chlamydia infection have a higher
organism load implying that those with symptomatic in-
fection may be more likely to experience treatment failure
[32]. The meta-analyses of urogenital treatment efficacy
found that the efficacy for azithromycin was lower for
those with symptomatic infection compared with doxycyc-
line [18]. It is unclear why this is so and suggests that per-
haps a longer duration of azithromycin may be needed [34]
with animal studies suggesting chlamydia shedding was
higher in those which were persistently infected and that
extended courses can overcome persistent infections [35].
Differences in the pharmacokinetic properties of
azithromycin and doxycycline may have an impact on
treatment efficacy
Doxycycline is highly lipid soluble which facilitates its rapid
distribution into tissue and site of infection. On the other
hand, azithromycin is delivered to the site of infection via
phagocytic cells produced during the immune response to
infection [36]. Data from animal studies suggest that, unlike
urogenital sites, the immune response in the gastrointes-
tinal tract is down-regulated so that chlamydia can con-
tinue to replicate and grow. If the innate immune response
in humans is similarly down-regulated, then it is possible
that there will be a reduction in phagocytes recruited to de-
liver azithromycin to the infection site. This is supported by
mouse studies that have shown that chlamydiae resident in
the gastrointestinal tract are not as susceptible to clearance
by azithromycin as they are in the genital tract, [37] and a
recent human study than found a dampened inflammatory
response in the rectum in response to chlamydia [38]. This
may explain in part the lower efficacy of azithromycin in
rectal tissue compared with cervical tissue and the lower ef-
ficacy of azithromycin compared with doxycycline in rectal
tissue. Nevertheless, pharmacokinetic data on the effective
concentrations of azithromycin in rectal mucosa are urgently
needed to determine whether a longer dosing regimen of
azithromycin is needed for anorectal chlamydia infections.
Persistent chlamydia infection may reduce treatment
efficacy
Chlamydia persistence is another factor that might con-
tribute to reduced treatment efficacy. CT, under the
selective pressure of beta-lactam antibiotics, [39]
interferon-gamma (IFN-Ƴ) or deprivation of nutrients
such as iron and amino acids (e.g., tryptophan), can
enter a persistent, metabolically inactive state containing
enlarged reticulum bodies known as aberrant bodies
(AB) [30, 40]. It is unclear how often the development of
ABs occurs in vivo and whether it is due to either peni-
cillin or IFN-Ƴ exposure, but ABs have been observed in
in vivo samples from patients using electron microscopy
[41]. In vitro, ABs are viable, but non-infectious and
semi-refractory to treatment with azithromycin or doxy-
cycline, depending on the cause of persistence. In this
persistent state the organism can be detected by NAAT.
A recent in vitro study examining the impact of β-
lactam antibiotics on chlamydia persistence [39] found
that all penicillins tested induced the formation of ABs
with a 95 % reduction in chlamydia’s infectivity. Upon
removal of the antibiotics, the chlamydia became infec-
tious again, but β-lactam-induced persistent chlamydia
was less susceptible to azithromycin in vitro [35]. There-
fore, the question begs whether the marked increase in
the use of beta-lactam antibiotics in recent years, [42]
including its use in treating increases numbers of syph-
ilis infections among gay men, [43] is contributing to
antibiotic-induced persistence and whether increasing
the duration of treatment can overcome this persistence
[34] as has been demonstrated in animals [35].
IFN-Ƴ is generated as part of the innate immune re-
sponse to chlamydia in humans and it triggers particular
immune pathways which act to starve chlamydia of the
essential amino acid tryptophan, leading to the develop-
ment of ABs. In contrast to beta-lactam induced per-
sistence, IFN-Ƴ exposure in vitro, makes chlamydia
more resistant to doxycycline, but still susceptible to
azithromycin [44].
Co-infection with herpes simplex virus can also con-
tribute to persistence [45–48] while HIV co-infection
does not [49]. Interestingly herpes co-infection does not
mediate chlamydia persistence by any currently under-
stood inducers, but through a novel mechanism that is
yet to be fully understood.
Results from cohort studies examining the chlamydia
isolates from those failing treatment among women [50]
will provide useful insights in the possible reasons for
treatment failure with similar studies needed with ano-
rectal infections among MSM.
The microbiome may play a role in treatment efficacy
Genital chlamydia has a unique interaction with their
human host. The human response to infection (including
chlamydia) is to produce IFN-Ƴ, which, among a host
of pathways, upregulates the enzyme indoleamine 2,3-
dioxygenase (IDO) which depletes tryptophan. The
genital strains of chlamydia are tryptophan auxotrophs
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but have retained the trpBA genes in the tryptophan
biosynthesis pathway. This enables them to back syn-
thesise tryptophan from indole, a compound that can
be present in the ano-genital tract as a product of some
groups of bacteria (Eg: Prevotella, Fusobacterium, E.
Coli) [51]. The availability of indole in the genital tract
(the levels will vary depending on the composition of the
microbiome), could rescue (i.e., recover or reactivate)
chlamydia at this site from “attack” by the host [51, 52].
The balance of indole-producing bacteria in the genital
microbiome could therefore influence whether an infec-
tion is acquired, is cleared or becomes persistent. Further
research investigating the role of the microbiome on chla-
mydia acquisition and clearance will help us understand
whether additional treatments such as probiotics or indole
antagonists could reduce an individual’s susceptibility to
infection, particularly re-infection.
Treatment failure may actually be a false positive
diagnosis
False positive diagnoses will happen if repeat testing
takes place within 4 weeks after treatment. NAAT re-
mains the recommended method for diagnosing CT
infections [13, 53]. However, current NAAT tests are
highly sensitive and do not differentiate between viable
and non-viable (dead) chlamydia nucleic acid. Studies
have shown that it is possible to detect chlamydia nu-
cleic acid for about three weeks following treatment
[12]. This is why length of time following treatment is
an important factor for determining when to conduct a
repeat test. Guidelines now recommend a “test for re-
infection” at 3 months after treatment rather than a “test
of cure” at 4 weeks post treatment to minimize the risk
of a false positive diagnosis [13]. Further research is
needed to develop new diagnostic tests that are able to
quantify messenger RNA, a marker of viable, replicating
organisms, rather than chlamydia DNA or ribosomal
RNA, and use these new tests when re-testing people
within 4 weeks after treatment.
The misdiagnosis of lymphogranuloma venereum may
reduce treatment efficacy
It is possible that in the absence of genotyping, cases of
lymphogranuloma venereum (LGV) will be missed, lead-
ing to treatment failure because a longer 21 day regimen
of doxycycline is recommended for the treatment of
LGV [13]. There are several serovars of chlamydia based
on the antigenic variations of the major outer membrane
protein with serovars A-C associated with trachoma,
D-K with urogenital, ocular and rectal infections and
L1-L3 associated with a systemic infection called lym-
phogranuloma venereum [54]. LGV is usually managed
on the basis of symptomatic clinical presentation, but
there is now evidence that LGV can be asymptomatic.
An audit of men attending an STI clinic in the
Netherlands found that 27 % of rectal LGV cases were
asymptomatic [55]. Other smaller studies in the UK and
Germany have found between 17 % and 53 % of cases of
rectal LGV among men were asymptomatic [56, 57].
These data suggest that rectal chlamydia infections
among MSM should be genotyped to ensure LGV is di-
agnosed and treated appropriately to minimise the risk
of treatment failure.
Auto-inoculation of chlamydia from rectal to cervical site
might contribute to treatment failure in women
There is increasing discussion in the literature about the
potential role of auto-inoculation of cervical chlamydia
infection from the rectal site. If rectal infection is indeed
more difficult to treat with azithromycin than cervical
infection, then auto-inoculation could contribute to
repeat cervical infection in women [58–60]. Anal sex is in-
creasing among heterosexual couples, with population-
based data from the UK showing that that 15-17 % of
heterosexual people reported anal sex in the last year, a 2–
3 fold increase since 1990 [61]. There is also evidence that
many women acquire rectal chlamydia infection in the ab-
sence of any reported anal sex [62].
A recent mathematical model estimated the impact
auto-inoculation may have on azithromycin and doxy-
cycline effectiveness for chlamydia in women and found
that when the possibility of auto-inoculation is taken
into account, doxycycline effectiveness is estimated to be
about 97 % compared to just 82 % for azithromycin [63].
However, it is important to note that the efficacy esti-
mates for treating rectal chlamydia included in the
model were based on data from observational studies
only and not from RCTs, reducing their validity.
Nevertheless, the available data suggest that we may
need to consider collecting rectal swabs from women for
chlamydia testing. However, rather than testing all
women for both rectal and cervical infection which
would increase testing costs substantially, consideration
should be given to conducting rectal testing for women
who present with repeat cervical chlamydia within three
months of treatment and for high risk women who re-
port anal sex. Further, consideration should be given to
treating women presenting with repeat chlamydia with
7 days of doxycycline rather than 1 gram azithromycin.
Treatment adherence may be important
It is important to note that azithromycin has definite ad-
vantages over doxycycline. It is single dose treatment, so
non-adherence is minimized. Non-adherence with doxy-
cycline can lead to treatment failure. In a secondary ana-
lysis of data from a RCT of men with non-gonococcal
urethritis who were randomly allocated to either azithro-
mycin or doxycycline, Khosropour and colleagues found
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that 28 % of men were non-adherent with their doxycyc-
line (based on self-report). Among those men treated for
chlamydia, those who were non-adherent had a nine fold
increase in microbiological failure at follow up (RR = 9.3;
95 % CI: 1.0, 89.2) [64]. An earlier study which used
Medication Event Monitoring System (MEMS) caps to
monitor compliance, found that among 58 men and
women who took at least 10 doses of doxycycline over
8 days, none (0 %; 95 % CI: 0 %, 6.1 %) failed microbio-
logical cure compared with 20 % failure in those who
took less than 10 doses (4/20; 95 % CI: 5.7 %, 43.3 %; p
< 0.01) [65].
Chlamydia screening and treatment could also be playing
a role in higher repeat infection rates
As chlamydia is mainly asymptomatic, [54] regular screen-
ing of priority populations is considered a key public
health control strategy. However there is ongoing debate
of the potential negative effects of a ‘screen and treat’ pol-
icy. Partial immunity protecting against chlamydia re-
infection has been demonstrated in animal models [66]
with early antibiotic treatment impairing this protective
immunity [67]. It has been suggested that while a ‘screen
and treat’ strategy may reduce the incidence of chlamydia
infection, it increases the risk of reinfection due to an
impairment in the development of a partial immunity
following treatment – this immunity occurring after a
spontaneous resolution in the infection – the so called
“arrested immunity hypothesis” [68]. Well-designed co-
hort studies of people at risk of chlamydia infection, with
serial collection of genital specimens and samples for
immunological investigation are needed to investigate this
“arrested immunity” hypothesis in humans to determine
whether treatment alters the immune response to infection.
Conclusion
Our review has highlighted that there remain a number
of gaps in our understanding about chlamydia treatment
efficacy and that these gaps will continue to have impli-
cations for the clinical management of chlamydia infec-
tions; clinicians will continue to be concerned about the
possibility of treatment failure in patients who present
with repeat chlamydia infection. Although it is unlikely
that antimicrobial resistance is an issue for chlamydia,
formal mechanisms for the ongoing surveillance of chla-
mydia antimicrobial sensitivity should be established.
While, most of these repeat infections will be due to re-
infection, a small proportion may be false positive diag-
noses because of retesting too early following treatment,
and some will represent true treatment failure as a result
of the mechanisms described above. The use of more
discriminatory tests for detecting LGV and the develop-
ment of tests to detect messenger RNA will improve
clinical management of chlamydia.
Considerable gaps in the evidence about the most effi-
cacious treatment for rectal chlamydia remain. RCTs
comparing doxycycline and azithromycin are urgently
needed but they must be must be double blind and pla-
cebo controlled to ensure that the risk of re-infection is
similar between treatment arms; it is possible that taking
a daily dose (as is required for doxycycline) may deter
people from resuming sexual activity while taking treat-
ment. Well-designed cohort studies of people at risk of
chlamydia with serial genital-sampling will help de-
termine the role of the immune response and genital
microbiome in chlamydia acquisition and clearance and
further our understanding about chlamydia persistence
so that more efficacious treatments can be used. How-
ever, regardless of all the concern about azithromycin,
we must be careful not to disregard this drug too prema-
turely based on the currently available data; azithromy-
cin is a drug that can attain and sustain high tissue
concentrations following a single dose with minimal is-
sues with adherence and mild side effects, and it is
effective for over 94 % of urogenital infections.
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